Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • Gepotidacin: A Breakthrough Bacterial Type II Topoisomera...

    2026-02-07

    Gepotidacin: Unlocking the Power of Bacterial Type II Topoisomerase Inhibition in Antibacterial Research

    Principle Overview: Mechanism and Research Significance

    Gepotidacin (GSK2140944) is a novel, first-in-class triazaacenaphthylene bacterial type II topoisomerase inhibitor that targets the core of bacterial DNA replication. By binding uniquely to both DNA gyrase and topoisomerase IV, Gepotidacin disrupts DNA supercoiling and relaxation, inducing single-strand DNA breaks and halting bacterial proliferation. Unlike fluoroquinolones, it acts at a distinct site, enabling potent efficacy against fluoroquinolone-resistant strains and multidrug-resistant organisms.

    As detailed in translational studies (see mechanistic overview), Gepotidacin’s dual inhibition of DNA gyrase and topoisomerase IV represents a leap forward for the DNA gyrase and topoisomerase IV inhibition pathway. This is vital for antibiotic resistance research, novel antibiotic development, and translational studies on bacterial DNA replication inhibition.

    Supplied by APExBIO, Gepotidacin (CAS No. 1075236-89-3, SKU: BA1220) is provided as a solid, with a molecular weight of 448.52 (C24H28N6O3), and should be stored at -20°C for optimal stability.

    Experimental Workflows: Stepwise Protocols and Enhancements

    1. In Vitro Antibacterial Activity Testing

    • Stock Preparation: Dissolve Gepotidacin in DMSO or sterile water to prepare a 10 mM stock. Avoid long-term storage of solutions; prepare fresh aliquots as needed.
    • Range-Finding: For in vitro assays, typical working concentrations span 0.015–32 μM, accommodating MIC determination for a diversity of bacterial targets.
    • MIC Determination: Use broth microdilution protocols to determine MIC50 and MIC90 values. Gepotidacin achieves MIC90 of 2 μM for Escherichia coli, 0.12 μM (MIC50) and 0.5 μM (MIC90) for Neisseria gonorrhoeae, 0.5 μM for MRSA, and 0.25 μM for Streptococcus pyogenes.
    • DNA Supercoiling/Relaxation Assays: Employ supercoiled plasmid DNA with purified bacterial DNA gyrase or topoisomerase IV in the presence of varying Gepotidacin concentrations. Measure inhibition of negative supercoiling (IC50 ≈ 0.047 μM) and positive supercoil relaxation (IC50 ≈ 0.6 μM).
    • DNA Cleavage Assays: Quantify single-stranded DNA breaks with EC50 values of 0.13 μM (negatively supercoiled DNA) and 0.18 μM (positively supercoiled DNA), leveraging agarose gel electrophoresis and densitometry.

    2. In Vivo Pharmacokinetic and Infection Models

    • Dosing Regimens: To simulate human pharmacokinetics, administer 1500 mg orally twice daily for urinary tract infection models, or two 3000 mg oral doses for urogenital gonorrhea models.
    • Readout: Monitor bacterial burden (cfu/mL) in infected tissues and clinical symptom resolution. Gepotidacin demonstrates robust eradication of multidrug-resistant pathogens (see translational insights).
    • Controls: Include fluoroquinolone-resistant and multidrug-resistant clinical isolates to benchmark Gepotidacin’s resistance-breaking potential.

    3. High-Throughput Screening Integration

    • Adapt Gepotidacin as a positive control in pathway-based or synthetic lethal screens targeting bacterial topoisomerase pathways, in line with frameworks described by Santa Maria et al. (2017). This enables benchmarking novel inhibitors or validating compound-target engagement.
    • Combine with biophysical profiling (e.g., ALIS affinity mass spectrometry) to map target engagement and efficacy, as pioneered in the reference study.

    Advanced Applications and Comparative Advantages

    Gepotidacin’s unique mode of action and broad-spectrum activity provide several research advantages:

    • Resistance-Breaking Efficacy: Outperforms classical fluoroquinolones against resistant clinical isolates, critical for antibiotic resistance research and multidrug-resistant bacterial infection models.
    • Dual Enzyme Targeting: By simultaneously inhibiting both DNA gyrase and topoisomerase IV, Gepotidacin blocks essential bacterial DNA processes, minimizing escape mutations and resistance development (see comparative analysis).
    • Translational Utility: Clinical data support its use in uncomplicated urinary tract infection and gonorrhea models, with human-simulated dosing regimens yielding durable pathogen clearance.
    • Quantitative Performance: Gepotidacin exhibits potent, quantifiable inhibition: IC50 values as low as 0.047 μM for S. aureus gyrase, and robust MICs (≤0.5 μM) against MRSA and Neisseria gonorrhoeae.

    These properties position Gepotidacin as a gold-standard tool compound for validating new pathways, benchmarking next-generation antibacterials, and exploring uncharted mechanisms of bacterial DNA replication inhibition.

    For cell-based viability and cytotoxicity assays, the article Gepotidacin (GSK2140944): Reliable Solutions for Antibiotic Research offers scenario-driven guidance for integrating Gepotidacin into modern antibacterial workflows, complementing the present protocol-focused discussion.

    Troubleshooting and Optimization Tips

    • Solubility Management: Prepare fresh Gepotidacin solutions prior to each experiment. Avoid repeated freeze-thaw cycles and do not store working solutions long-term.
    • Assay Sensitivity: For MIC assays, ensure standardized inoculum sizes and media composition. Variability in inoculum density or pH can influence apparent MICs.
    • Control Selection: Always include both susceptible and resistant strains to validate specificity and resistance-breaking action.
    • Data Interpretation: Biphasic or partial inhibition curves may indicate compound precipitation or off-target effects—optimize solvent content or sample mixing accordingly.
    • Interference Checks: In high-throughput screens, include DMSO-only controls and confirm hits with orthogonal assays to rule out nonspecific effects, as emphasized in the referenced Santa Maria et al. framework.

    According to Gepotidacin (GSK2140944): Mechanistic Breakthroughs and Strategies, integrating orthogonal validation steps and mechanistic readouts (e.g., DNA cleavage patterns) can resolve ambiguous screening outcomes and guide hit prioritization.

    Future Outlook: Gepotidacin in Next-Generation Antibacterial Discovery

    Gepotidacin’s clinical trajectory and molecular innovation set the stage for a new era of antibiotic discovery. Its validated efficacy in tackling complicated and uncomplicated bacterial infections—including those caused by fluoroquinolone-resistant and multidrug-resistant strains—makes it an indispensable asset for translational and bench research alike.

    The integration of Gepotidacin into high-throughput screens, phenotypic assays, and mechanistic studies (as illustrated by Santa Maria et al., 2017) paves the way for identifying novel targets, refining pathway-based screening, and accelerating the development of next-generation triazacyclopentadiene antibacterial agents.

    Moreover, leveraging Gepotidacin’s unique interaction with the bacterial topoisomerase pathway enables the design of new compounds with optimized selectivity and minimized resistance potential. The synergy between compound design, biophysical profiling, and translational infection models will be central to overcoming current gaps in the antibiotic pipeline.

    For reliable sourcing and technical support, APExBIO remains the trusted supplier of Gepotidacin (product page), empowering researchers at every stage from bench discovery to translational validation.


    Further Reading:
    To expand your strategies for deploying Gepotidacin and related agents, explore these articles:

    By leveraging these resources and the rigorous protocols outlined above, scientists can maximize the impact of Gepotidacin in antibacterial research, accelerate the fight against antibiotic resistance, and contribute to the next wave of novel antibiotic development.